Tetrazine-Trans-Cyclooctene Ligation as the Basis of PET/SPECT Probes and Radiotherapies

Technology

Molecular imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) rely on radiolabeled derivatives, enabling visualizing of biological processes within living organisms and advancing early disease diagnosis in the fields of oncology, cardiology, and neurology. However, radioisotopes used in imaging raise concerns about radiation exposure because they emit ionizing radiation, which can harm living tissues. Additionally, their finite half-life requires frequent replenishment of radioisotope stocks, leading to increased operational costs and complexity, and limiting the available time for imaging procedures. Tetrazine-based ligation, pioneered by researchers at the University of Delaware, enable a pretargeted approach for PET/SPECT imaging and therapy. This technique offers enhancements in sensitivity of imaging contrast and minimization of the radiation exposure. The innovation involves incorporating Fluorine-18 (18F) into tetrazines and trans-cyclooctenes, showcasing the high efficiency of tetrazine- trans -cyclooctene ligation with 18F-labeled derivatives. 18F is particularly valuable for developing PET radiopharmaceuticals due to its stability, extended half-life, and its applications in aiding the diagnosis and monitoring of various cancers, including prostate, lung, head and neck, and pancreatic cancers. Furthermore, tetrazine-based ligation allows for the utilization of short-lived radionuclides with advantageous radiophysical properties, expanding its applications in clinical diagnostics and treatments.

Benefits

  • Bioorthogonal ligations offer the advantage of rapid reaction rates, enabling efficient 18F probes for a wide range of imaging and diagnostic applications.
  • The use of bioorthogonal ligation for delivering 18F probes ensures specificity, selectively attaching the radiolabel to target biomolecules, and minimizing off-target effects.
  • 18F-labeled compounds are extensively used in the fields of oncology, including prostate, breast, lung, glioblastoma, hepatocellular carcinoma, head and neck, colorectal, and pancreatic cancers.
  • This invention holds significant potential in neoplastic research, leveraging the advantages of 18F half-life, metabolization, biodistribution, and protein-binding kinetics for enhanced diagnostics.

Applications

  • Pharmaceutical companies
  • Medical imaging equipment and probes manufacturers
  • Diagnostic laboratories and radiology centers
  • Biotechnology